In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...

The price of crude oil dropped to $62.46 a barrel Monday morning, part of a downward trend that some analysts say could ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...

Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.  Ozempic, a drug approved for Type 2 diabetes, cardiovascular ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.